SILVER SPRINGS, NV / ACCESSWIRE / January 3, 2017 / Kasten, Inc. (OTC PINK: KAST) announced today it has signed a Joint Venture agreement with Thru Pharma LLC dba DAKOTA Life Sciences for the purpose of promoting the development and marketing of Site Specific Penetration Technology (SSPT™ ) biopharmaceutical products.
Dakota Life Sciences is engaged in developing innovative health products utilizing SSPT™ technologies. These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as genomics-based companion diagnostics.
Under the terms of the Joint Venture Agreement, both parties will have equal ownership rights. “This new joint venture is uniquely positioned to optimize the development of DAKOTA’s biopharmaceutical product line. Together we will launch their portfolio of products to the market place. This JV further compliments our roll-up strategy of developing and commercializing innovative medical solutions,” stated Jose Delgado, CEO of Kasten, Inc.
DAKOTA Life Sciences is a leading anti-infectives private pharmaceutical Company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections. Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
SOURCE: Kasten, Inc